Taisho Pharmaceutical Holdings Co., Ltd. (4581)の価格はいくらですか

Taisho Pharmaceutical Holdings Co., Ltd. (4581)の価格は$55.98です

Taisho Pharmaceutical Holdings Co., Ltd. (4581)の時価総額は何ですか

Taisho Pharmaceutical Holdings Co., Ltd. (4581)の時価総額は$4.59Bです

Taisho Pharmaceutical Holdings Co., Ltd.（4581）の株価履歴

Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.

年	パフォーマンス
2024	-5.88%
2023	44.29%
2022	-12.35%
2021	-26.86%
2020	-13.22%
2019	-31.25%
2018	37.86%
2017	-3.39%
2016	19.38%
2015	10.57%
2014	-9.39%
2013	-5.87%
2012	1.14%
2011	0.00%

年

パフォーマンス

2024

-5.88%

2023

44.29%

2022

-12.35%

2021

-26.86%

2020

-13.22%

2019

-31.25%

2018

37.86%

2017

-3.39%

2016

19.38%

2015

10.57%

2014

-9.39%

2013

-5.87%

2012

1.14%

2011

0.00%

企業	株価	変化率 1年%	国
MERCK Kommanditgesellschaft auf Aktien MER.SW	$171.67	-	DE
Merck KGaA MRK.DE	$166.06	32.31%	DE
Takeda Pharmaceutical Company Limited 4502.T	$38.23	28.07%	JP
Galderma Group AG GALD.SW	$223.18	30.81%	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$20.96	14.80%	IN

企業

株価

変化率 1年%

国